Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för vorinostat. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

8 träffar

Bibliografisk träff 2013-11-01

The histone deacetylase inhibitor vorinostat prevents TNFα-induced necroptosis by regulating multiple signaling pathways.

Wang D, Zhao M, Chen G, Cheng X, Han X, Lin S, Zhang X, Yu X.

Apoptosis · research support, non-u.s. gov't; journal article · DOI 10.1007/s10495-013-0866-y

Bibliografisk träff 2013-07-03

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor.

Iwamoto M, Friedman EJ, Sandhu P, Agrawal NG, Rubin EH, Wagner JA.

Cancer Chemother Pharmacol · review; journal article · DOI 10.1007/s00280-013-2220-z

Bibliografisk träff 2013-06-23

Synergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells.

Kwak TW, Kim DH, Chung CW, Lee HM, Kim CH, Jeong YI, Kang DH.

Evid Based Complement Alternat Med · research-article; journal article · DOI 10.1155/2013/185158

Bibliografisk träff 2013-06-11

A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.

Andersen CL, McMullin MF, Ejerblad E, Zweegman S, Harrison C, Fernandes S, Bareford D, Knapper S, Samuelsson J, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Hasselbalch HC.

Br J Haematol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1111/bjh.12416

Bibliografisk träff 2013-01-21

Comprehensive gene expression profiles of NK cell neoplasms identify vorinostat as an effective drug candidate.

Karube K, Tsuzuki S, Yoshida N, Arita K, Kato H, Katayama M, Ko YH, Ohshima K, Nakamura S, Kinoshita T, Seto M.

Cancer Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.canlet.2012.12.022

Bibliografisk träff 2013-01-08

Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms.

Silva G, Cardoso BA, Belo H, Almeida AM.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0053766

Bibliografisk träff 2012-08-09

A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).

Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Espinoza-Delgado I, Weigel BJ, Blaney SM.

Pediatr Blood Cancer · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1002/pbc.24271

Bibliografisk träff 2011-06-10

Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.

Sun JY, Tseng H, Xu L, Hunter Z, Ciccarelli B, Fulciniti M, Zhu B, Maghsoudi K, Yang G, Gong P, Zhou Y, Liu X, Munshi NC, Patterson CJ, Treon SP.

Leuk Lymphoma · research support, non-u.s. gov't; journal article · DOI 10.3109/10428194.2011.577850